PARP-1 in Juvenile Idiopathic Arthritis-associated IL-10 Promoter Polymorphisms
PARP-1 与幼年特发性关节炎相关的 IL-10 启动子多态性
基本信息
- 批准号:7911718
- 负责人:
- 金额:$ 7.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-10 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityArthritisAutoimmune ProcessB-LymphocytesBindingBlood CellsCellsChildhoodChromatinChronicChronic Childhood ArthritisDNA RepairDendritic CellsDiseaseGene ExpressionGenetic PolymorphismGenetic VariationGenotypeHumanIL10 geneImmuneInflammationInflammatoryInflammatory ResponseInterleukin-10InvestigationLeadMediatingMethodsMolecularNuclearPathogenesisPatientsPoly(ADP-ribose) PolymerasesProductionProteinsRegulatory PathwayT-LymphocyteTherapeutic InterventionTranscription Repressor/CorepressorTumor Necrosis Factor-alphaTumor Necrosis FactorsWorkZinc Fingersabstractingbasecytokineeffective therapymacrophagenovelpromoterpublic health relevance
项目摘要
DESCRIPTION (provided by applicant):
ABSTRACT: Juvenile idiopathic arthritis (JIA) is the most common chronic autoimmune inflammatory disease in childhood. Lower IL-10 production in patients with the -1082A/-819T/-592A (ATA) IL-10 promoter genotype can lead to excessive inflammatory responses with more severe arthritis, suggesting a direct association of IL-10 gene variants with JIA. Recently, we identified poly(ADP-ribose) polymerase 1 (PARP-1) as a novel transcriptional repressor of IL-10 gene expression with enhanced binding affinity for the ATA IL-10 promoter genotype. Therefore, we hypothesize that PARP-1-mediated suppression of IL-10 production is important for the pathogenesis of JIA, and that removing this suppression could result in effective therapies for treating patients with JIA. IL-10 is a pleiotropic cytokine produced by a variety of immune cells including T cells, B cells, macrophages and dendritic cells. It inhibits the production of proinflammatory cytokines and suppresses the effects of proinflammatory cytokines such as tumor necrosis factor-a (TNF-a). PARP-1 is a highly conserved nuclear zinc- finger protein involved in DNA repair, chromatin decondensation and gene expression. Our recent work has demonstrated that PARP-1 binding to the IL-10 promoter is enhanced by the -592A sequence polymorphism, and that over-expression of PARP-1 results in lower IL-10 production in human macrophages. However, the mechanistic details of how IL-10 is regulated by PARP-1 are unknown, and must be elucidated in order to develop new therapies based on targeting PARP-1. Therefore, in this project, we will: (1) elucidate the mechanistic detail of how PARP-1 regulates IL-10 gene expression at the molecular level. (2) develop methods capable of reversing PARP-1-mediated suppression of IL-10 production in JIA patients expressing the ATA IL-10 promoter genotype. This study will enable us to identify key steps in the regulatory pathway that may be explored as potential targets of therapeutic intervention in JIA. Moreover, the proposed investigation into ways to inhibit PARP-1 activity in JIA patients' blood cells of the susceptible type may eventually help correct their IL-10 production deficit, thus restoring the patients' own immune capacity to control arthritic inflammation.
PUBLIC HEALTH RELEVANCE:
RELEVANCE Elucidation of the molecular mechanisms whereby PARP-1 regulates IL-10 gene expression will enable us identify key steps in the regulatory pathway that may be explored as potential targets of therapeutic intervention in juvenile arthritis. Moreover, the proposed investigation into ways to inhibit PARP-1 activity in arthritis patients' blood cells may eventually help correct their IL-10 production deficit, thus restoring the patients' own immune capacity to control arthritic inflammation.
描述(由申请人提供):
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianguo Liu其他文献
Jianguo Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianguo Liu', 18)}}的其他基金
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10634764 - 财政年份:2022
- 资助金额:
$ 7.33万 - 项目类别:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10511464 - 财政年份:2022
- 资助金额:
$ 7.33万 - 项目类别:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
MALT1抑制剂对内分泌耐药乳腺癌的临床前测试
- 批准号:
10579334 - 财政年份:2022
- 资助金额:
$ 7.33万 - 项目类别:
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
MALT1抑制剂对内分泌耐药乳腺癌的临床前测试
- 批准号:
10435975 - 财政年份:2022
- 资助金额:
$ 7.33万 - 项目类别:
A new target for host-directed therapy against TB infection
针对结核感染的宿主定向治疗的新靶点
- 批准号:
10256733 - 财政年份:2020
- 资助金额:
$ 7.33万 - 项目类别:
A new target for host-directed therapy against TB infection
针对结核感染的宿主定向治疗的新靶点
- 批准号:
10057563 - 财政年份:2020
- 资助金额:
$ 7.33万 - 项目类别:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
IL28B基因变异介导的丙型肝炎病毒清除机制
- 批准号:
8445769 - 财政年份:2013
- 资助金额:
$ 7.33万 - 项目类别:
Mechanisms of IL28B genetic variation-mediated clearance of hepatitis C virus
IL28B基因变异介导的丙型肝炎病毒清除机制
- 批准号:
8732600 - 财政年份:2013
- 资助金额:
$ 7.33万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
8221172 - 财政年份:2012
- 资助金额:
$ 7.33万 - 项目类别:
The role of tristetraprolin in control of breast cancer progression
三四脯氨酸在控制乳腺癌进展中的作用
- 批准号:
9079413 - 财政年份:2012
- 资助金额:
$ 7.33万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
$ 7.33万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 7.33万 - 项目类别:
Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
- 批准号:
10068495 - 财政年份:2024
- 资助金额:
$ 7.33万 - 项目类别:
Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 7.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
- 批准号:
24K19850 - 财政年份:2024
- 资助金额:
$ 7.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
$ 7.33万 - 项目类别:
Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
- 批准号:
489316 - 财政年份:2023
- 资助金额:
$ 7.33万 - 项目类别:
Operating Grants
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
- 批准号:
23K14987 - 财政年份:2023
- 资助金额:
$ 7.33万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
$ 7.33万 - 项目类别:
Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
- 批准号:
10733789 - 财政年份:2023
- 资助金额:
$ 7.33万 - 项目类别: